Frequency of factor V Leiden (G1691A), prothrombin (G20210A) and methylenetetrahydrofolate reductase (C677T) genes mutations in woman with adverse pregnancy outcome

Journal of the Turkish German Gynecology Association

Volumn 7, Issue 3, 2006, Pages 195-201

  Ulukuş, Murat ^a   Eroǧlu, Zuhal ^a   Yeniel, Ahmet Özgür ^a   Toprak, Erzat ^a   Kosova, Buket ^a   Turan, Özgür Deniz ^a   Ulukuş, Mustafa ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Adverse pregnancy outcome; Hereditary thrombophilias

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; C 677 T; G 1691 A; G 20210 A; PROTHROMBIN;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FETUS DEATH; GENE MUTATION; GENOTYPE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREECLAMPSIA; PREGNANCY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STILLBIRTH; THROMBOPHILIA;

EID: 33750340055     PISSN: 13090399     EISSN: 13090380     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bertina RM, Koelman BPC, Koster T. Mutations in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
3. Frosst P, Blom HJ, Milos R et al. A candidate risk factor for vascular disease: a common mutation in the methyltetrahydrofolate reductase. Nat Genet 1995;10:111-3.
4. Hayashi M. Aetiology of preeclampsia and thrombophilic genetic mutations. Clin Sci 2003;105:269-71.
5. Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003;109:73-81.
6. Kujovich JL. Thrombophilia and pregnancy complications. Am J Obstet Gynecol 2004;191:412-24.
7. Khong TY, Pearce JM, Robertson WB. Acute atherosis in preeclampsia: maternal determinant and fetal outcome in the presence of the lesion. Am J Obstet Gynecol 1987;157:360-3.
8. Roberts JM, Taylor RN, Muscu TJ et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-4.
9. De Vries JIP, Dekker GA, Huijgens PC et al. Hyperhomocysteinemia and protein S deficiency in complicated pregnancies. Br J Obstst Gynecol 1997;104:248-54.
10. van-Pampus MG, Dekker GA, Wolf H et al. High prevalence of hemostatic abnormalities in women with history of severe preeclampsia. Am J Obstet Gynecol 1999;180:1146-50.
11. Martinelli P, Grandone E, Collaizzo D et al. Familial tbrombophilia and the occurrence of fetal growth restriction. Haematologica 2001;86:428-31.
12. Livingston JC, Barton JR, Park V et al. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001;185:153-7.
13. Alfirevic Z, Mousa HM, Martlew V et al. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet Gynecol 2001;97:753-9.
14. Verspyck E, Le Cam-Duchez V, Goffinet F et al. Thrombophilia and immunologic disorders in pregnancies as risk factors for small gestational age infants. Br J Obstet Gynecol 2002;109:28-33.
15. Kupferminc MJ, Eldor A, Steinman N et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Eng J Med 1999;340:9-13.
16. Mello G, Parretti E, Martini E et al. Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies. Haemostasis 1999;29:197-203.
17. von Tempelhoff GF, Heilmann L, Spanuth E et al. Incidence of the factor V Leiden mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP syndrome. Thromb Res 2000;100:363-5.
18. Grandone E, Margaglione M, Colaizzo D et al. Factor V Leiden, C>T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997;77:1052-4.
19. Dizon-Towson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902-5.
20. Rigo J Jr, Nagy B, Fintor L et al. Maternal and neonatal outcome of preeclamptic pregnancies:the potential roles of factor V Leiden mutation and 5, 10 methylentetrahydrofolate reductase. Hypertens Pregnancy 2000;19: 163-72.
21. Kobashi G, Yamada H, Asano T et al. The factor V Leiden mutation is not a common cause of pregnancy-induced hypertension in Japan. Semin Thromb Hemost 1999;25:487-9.
22. Lindoff C, Ingemarsson I, Martinsson G et al. Preeclampsia is associated with reduced response to activated protein C. Am J Obstet Gynecol 1997; 176:457-60.
23. Currie L, Peek M, McNiven M et al. Is there an increased maternal-infant prevalence of factor V Leiden in association with severe preeclampsia? BJOG 2002;109:191-6.
24. Grandone E, Margaglione M, Colaizzo D et al. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost 1999;81:349-52.
25. Kupferminc MJ, Fait G, Many A et al. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 2000;96:45-9.
26. Prasmusinto D, Skrablin S, Hofstaetter C et al. The methylentetrahidrofolat reductase 677 C->T polymorphism and preeclampsia in two populations. Obstet Gynecol 2002;99:1085-92.
27. Kobashi G, Yamada H, Asano T et al. Absence of association between a common mutation in the methylentetrahidrofolat reductase gene and preeclampsia in Japanese women. Am J Med Genet 2000;93:122-5.
28. Laivuori H, Kaaja R, Ylikorkola O et al. 677 C->T polymorphism of the methylentetrahidrofolat reductase gene and preeclampsia. Obstet Gynecol 2000;96:277-80.
29. Kaiser T, Brennecke SAP, Moses EK. C677T methylentetrahidrofolat reductase polymorphism is not a risk factor for preeclamsia/eclampsia among Australian women. Hum Hered 2001;51:20-2.
30. Brenner B, Sarig G, Weiner Z et al. Thrombophilic polymorphism are common in women with fetal loss without apparent cause. Thromb Haemost 1999;82:6-9.
31. Foka ZJ, Lambropoulos AF, Saravelos H et al. Factor V Leiden and G20210A prothrombin mutations, but not methylentetrahidrofolat reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000; 15:458-62.
32. Reznikoff-Etievan MF, Cayol V, Carbonne B et al. Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. BJOG 2001;108:1251-4.
33. Tormene D, Simioni P, Prandoni P et al. The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Haemost 1999;82:1237-9.
34. Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913-6.
35. Meinardi JR, Middeldorp S, de Kam PJ et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999;130:736-9.
36. Unfried G, Griesmacher A, Weismuller W et al. The C677T polymorphism of the methylenetetrahidrofolat reductase gene and idiopathic recurrent miscarriage. Obstet Gynecol 2002;99:614-9.
37. van der Molen EF, Verbruggen B, Novakova I et al. Hyperhomocysteinemia and other risk factors in women with placental vasculopathy. BJOG 2000;107:785-91.
38. Gris JC, Quere I, Monpeyroux F et al. Case-control study of the frequency of thrombophilic disorders in couples with late fetal loss and no thrombotic accident-the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thromb Haemost 1999;81:891-9.
39. Hohlagschwandtner M, Unfried G, Heinze G et al. Combined thrombophilic polymorphisms in women with idiopathic recurrent miscarriage. Fertil Steril 2003;79:1141-8.
40. Holmes ZR, Regan L, Chilcot I, Cohen H. The C677T MTHFR gene mutation is not predictive of risk for recurrent fetal loss. Br J Haematol 1999;105:98-101.
41. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901-8.
42. Alonso A, Soto I, Urgelles MF et al. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol 2002;187: 1337-42.
43. Kupferminc MJ, Many A, Bar-Am A et al. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. BJOG 2002;109:1373-6.
44. Infante-Rivard C, Rivard GE, Yotov WV et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Eng J Med 2002;347:19-25.
45. Murphy RP, Donoghue C, Nallen RJ et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylentetrahidrofolat polymorphism in pregnancy. Arterioscler Thromb Vasc Biol 2000;20:266-70.
46. Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol 1998;179:1567-70.
47. Facchinetti F, Marozio L, Grandone E et al. Thrombophilic mutations are a main risk factor for placental abruption. Haematologica 2003;88:785-8.
48. Sazci A, Ergul E, Kaya G, Kara I. Genotype and allele frequencies of the polymorphic methylenetetrahidrofolat reductase gene in Turkey. Cell Biochem Funct 2005;23:51-4.
49. Higgins JR, Kaiser T, Moses EK et al. Prothrombin G20210A mutation: is it associated with preeclampsia? Gynecol Obstet Invest 2000;50:254-7.
50. Ayyildiz O, Kalkanli S, Batun S et al. Prothrombin G20210A gene mutation with LightCycler polymerase chain reaction in venous thrombosis and healthy populations in southeast of Turkey. Heart Vessels 2004;19:164-6.